EHA 2019 Frontline brentuximab vedotin + AVD provides durable benefit over ABVD in patients with stage ... Read more
EHA 2019 Acalabrutinib delays disease progression in patients with relapsed/refractory chronic lymphocy... Read more
EHA 2019 Voxelotor induces robust improvements in anemia in patients with sickle cell disease Read more